25,729 articles
Ravi Thadhani
Ravi Thadhani is an American nephrologist-scientist who is chief medical officer of Cedars-Sinai Health System and was elected to the National Academy of Medicine in 2025 for pioneering the first FDA-approved test to predict preeclampsia.
Ravidasvir hydrochloride
Ravidasvir hydrochloride (盐酸拉维达韦, PPI-668, ASC-16) is an oral pangenotypic HCV NS5A inhibitor used with sofosbuvir; developed via DNDi-Pharco collaboration, WHO EML-listed 2023, approved in Egypt, China, and Malaysia.
Ravine syndrome
Ravine syndrome, also called RAVINE leukoencephalopathy, is an extremely rare autosomal recessive genetic neurological disorder described on Reunion Island, causing infantile anorexia, intractable vomiting, and progressive encephalopathy.
Raw foodism
Raw foodism (rawism) is eating only or mostly uncooked, unprocessed food, typically nothing heated above 118°F (48°C); mostly raw vegan, with documented risks of B12 deficiency, weight loss, and foodborne illness.
Raxibacumab
Raxibacumab (ABthrax) is a human IgG1λ monoclonal antibody against anthrax protective antigen, FDA-approved December 14, 2012 under the Animal Rule for inhalational anthrax; dose 40 mg/kg IV, half-life 20–22 days, stockpiled in the US.
RAY1225
RAY1225 is an investigational biweekly GLP-1/GIP dual receptor agonist injection by Guangdong Raynovent Biotech (Zhongsheng Pharma), in phase 3 for obesity and type 2 diabetes, with phase 2 weight loss up to 21.18% at 24 weeks.
Raymond P. White Jr.
Raymond P. White Jr. is an American oral and maxillofacial surgeon and UNC-Chapel Hill professor elected to the Institute of Medicine in 1982, known for third molar clinical trials.
Raymond Sackler
Raymond Sackler (1920-2017), American psychiatrist and co-founder of Purdue Pharma with brother Mortimer; with wife Beverly a major philanthropist via the Raymond and Beverly Sackler Foundations; family later settled opioid lawsuits for up to $7.4 billion.
Raynaud syndrome
Raynaud syndrome (Raynaud's phenomenon, Raynaud's disease) is episodic vasospasm of digital arteries triggered by cold or stress, causing white-blue-red skin color changes; primary form is benign, secondary form links to connective tissue disease.
RBD5044
RBD5044: GalNAc-conjugated siRNA by Suzhou Ribo Life Science targeting ApoC3 for hypertriglyceridemia; second ApoC3 siRNA in clinic; phase 1 cut ApoC3 up to 84% and triglycerides up to 70%; phase 2 trials in Sweden and China.
RBD7022 (QLC7401)
RBD7022, known as QLC7401 in Greater China, is a GalNAc-conjugated siRNA targeting PCSK9 mRNA to lower LDL cholesterol, developed by Suzhou Ribo Life Science and licensed to Qilu Pharmaceutical.
RBx-10017609
RBx-10017609 (RBX 10017609) was an oral dual MMP-9/MMP-12 inhibitor developed by Ranbaxy with GSK for COPD; it completed Phase 1 safety studies and a 12-week Phase 2 proof-of-concept trial at 200 mg BID before being discontinued.
RBx-10558
RBx-10558 (PPD-10558) was a Ranbaxy-discovered HMG-CoA reductase inhibitor statin for dyslipidemia, licensed to PPD/Furiex in 2007; its Phase 2b trial in statin-associated myalgia (NCT01279590, 282 patients) missed its endpoint and development stopped in 2011.
RC148
RC148 (ABBV-1480) is a humanized IgG1 PD-1/VEGF bispecific antibody from RemeGen, in phase 3 for NSCLC and solid tumors in China and licensed ex-Greater China to AbbVie in 2026 for $650 million upfront plus up to $4.95 billion in milestones.
RCT trial (NCT00690326)
NCT00690326, a randomized triple-blind trial at Thiruvananthapuram Medical College, Kerala, tested a behavioral change communication model for physical activity in 86 women with type 2 diabetes; activity rose (p=0.007), HbA1c unchanged.
RCT trial (NCT00849004)
NCT00849004, a randomized factorial trial at Kaohsiung Veterans General Hospital, Taiwan, comparing silicone sheet, silicone gel, and paper tape for preventing hypertrophic scars and keloids on sternotomy and abdominal surgical wounds; started 2009, completed 2012, no results posted.
RCT trial (NCT04894344)
NCT04894344, a randomized controlled trial by Universidad Autonoma de Baja California in Tijuana, Mexico, testing a 4-week educational newsletter intervention to reduce sodium intake in university students aged 18-40, measured by 24-hour urinary sodium excretion and blood pressure.
RCT-PIDST trial
RCT-PIDST (NCT07712328) is a Phase 4 randomized trial at Huashan Hospital, Shanghai, testing prophylactic intraoperative desmopressin infusion to prevent hypernatremia after complex sellar region tumor surgery in 152 patients.
RCTVMSSG trial
RCTVMSSG (NCT02817256) is a randomized, double-blind UAE University trial comparing oral versus parenteral vitamin and mineral supplementation after sleeve gastrectomy at Tawam Hospital; 105 participants, iron-level primary endpoint, no posted results.
RDNS trial
RDNS (Rang-Din Nutrition Study, NCT01715038): cluster-randomized effectiveness trial in northwest Bangladesh, 4,011 pregnant women, 64 clusters, testing LNS and MNP home fortification during the first 1,000 days; LNS improved growth, development, and iron status.
Re-excision
Re-excision is a surgical procedure, used mainly after breast-conserving surgery for breast cancer, that removes additional tissue to clear positive or close margins on pathology.
Re-irradiation
Re-irradiation is a new radiotherapy course to a previously irradiated volume, with cumulative dose converted to EQD2 or BED to assess organ toxicity risk before summation.
Re-resection
Re-resection is a surgical procedure removing tissue again at a previously operated site, most often for residual or recurrent tumor, such as margin re-excision after lumpectomy.
ReabFalls trial
ReabFalls (NCT06175871) is a completed interventional trial by UQAC and CIUSSS Saguenay-Lac-Saint-Jean testing the Otago exercise program for fall prevention in older adults with neuromusculoskeletal disorders at La Baie Hospital, Quebec.
REACS study
REACS (NCT02415452), a Chinese retrospective cohort study by Capital Medical University, tested whether retinal artery lesion staging predicts MACCE and mortality in 660 acute coronary syndrome patients after drug-eluting stent implantation; Stage ≥2 lesions independently predicted adverse events.
Reaction patterns in inflammatory skin disease
Reaction patterns in inflammatory skin disease are the recurring microscopic tissue responses, six canonical patterns such as spongiotic and lichenoid, into which more than 100 named dermatoses are classified.
Reactive airway disease
Reactive airway disease (RAD) is an informal, non-diagnostic placeholder term for asthma-like wheezing and cough of unknown cause, used mostly in young children; distinct from asthma, COPD, and reactive airways dysfunction syndrome (RADS).
Reactive angioendotheliomatosis
Reactive angioendotheliomatosis (RAE) is a rare, benign, self-limiting cutaneous vascular proliferation with endothelial hyperplasia inside and around dermal vessels, occurring with systemic diseases such as endocarditis, renal disease, and peripheral vascular disease.
Reactive arthritis
Reactive arthritis, formerly Reiter's syndrome, is inflammatory joint disease following gut or urogenital infection (Chlamydia, Salmonella, Shigella, Yersinia), HLA-B27-associated, usually resolving within 6 to 12 months.
Reactive arthropathies
Reactive arthropathies, or reactive arthritis (ReA), formerly Reiter's syndrome: sterile HLA-B27-associated spondyloarthritis after gastrointestinal or genitourinary infection with Salmonella, Yersinia, or Chlamydia; most remit within 6-12 months.